AMIGO3 and demyelinating disease: Thus, compared to Lingo-1, our study highlights the potential of AMIGO3 as a more effective therapeutic target to decrease abnormal neural circuit formation in the immature brain after SC and demyelinating diseases, although further studies are required to fully elucidate the underlying mechanism.